• Open Access

Efficacy of Low- and High-Dose Trilostane Treatment in Dogs (< 5 kg) with Pituitary-Dependent Hyperadrenocorticism

Authors

  • K.-D. Cho,

    1. Laboratory of Veterinary Internal Medicine, Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
    Search for more papers by this author
  • J.-H. Kang,

    Corresponding author
    • Laboratory of Veterinary Internal Medicine, Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
    Search for more papers by this author
  • D. Chang,

    1. Laboratory of Veterinary Diagnostic Imaging, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
    Search for more papers by this author
  • K.-J. Na,

    1. Laboratory of Veterinary Laboratory Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
    Search for more papers by this author
  • M.-P. Yang

    1. Laboratory of Veterinary Internal Medicine, Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea
    Search for more papers by this author

  • This study was presented as a scientific abstract in poster form at the 2011 ACVIM Forum, Denver, CO

Corresponding author: J.-H. Kang, Department of Veterinary Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 361-763, Republic of Korea; e-mail: jhkang@chungbuk.ac.kr

Abstract

Background

Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH.

Objectives

To compare the efficacy of 2 trilostane protocols in the treatment of dogs with PDH.

Animals

Sixteen client-owned dogs with PDH and a body weight <5 kg.

Methods

Prospective observational study. Group A (n=9; low-dose treatment group) received 0.78 ± 0.26 mg of trilostane/kg PO every 12 h and group B (n = 7; high-dose treatment group) 30 mg of trilostane/dog PO every 24 h. All of the dogs were reassessed at 2, 4, 8, 12, 16, and 24 weeks after the initiation of treatment.

Results

An improvement in both ACTH-stimulated serum cortisol concentrations and clinical signs occurred more slowly in group A than in group B; however, after 20 weeks of treatment, 2/7 dog in group B had clinical signs and abnormal laboratory findings consistent with hypoadrenocorticism. At 24 weeks, an improvement in the clinical findings of all of the dogs in both groups was detected.

Conclusions and clinical importance

In dogs with PDH, twice-daily administration of low-dose trilostane is an effective approach to the management of PDH. In addition, our results suggest fewer potential adverse effects if trilostane is administered twice daily in the lower dose.

Ancillary